Patent ID: 6803375
Filing Date: 2004-10-12
Classification: A61K,A61P

Abstract:
A method for treating or preventing an autoimmune disorder, transplant rejection or graft-versus-host disease or for causing immunomodulation in a mammalian patient without causing substantial inhibition of cytochrome P-450, said method comprising the step of administering to the patient a therapeutically effective amount of a compound having the formula: Wherein,X, Y and Z are the same or different and are independently selected from CH2, O, S, NR1, N&boxH;CH, CH&boxH;N and R2â€”C&boxH;Câ€”R3, where R2 and R3 are H and wherein R2 and R3 may or may not be combined to form a saturated or unsaturated carbocyclic or heterocyclic ring, optionally substituted with one or more R groups and where R1 is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl and aroyl, optionally substituted with hydroxy, amino, substituted amino, cyano, alkoxy, halogen, trihaloalkyl, nitro, thio, alkylthio, carboxy and alkoxycarbonyl groups; R is selected from H, halogen, trihaloalkyl, hydroxy, acyloxy, alkoxy, alkenyloxy, thio, alkylthio, nitro, cyano, ureido, acyl, carboxy, alkoxycarbonyl, Nâ€”(R4)(R5) and a saturated or unsaturated, chiral or achiral, cyclic or acyclic, straight or branched hydrocarbyl group with from 1 to 20 carbon atoms, optionally substituted with hydroxy, halogen, trihaloalkyl, alkylthio, alkoxy, carboxy, alkoxycarbonyl, oxoalkyl, cyano and Nâ€”(R4)(R5) group, where R4 and R5 are selected from H, alkyl, alkenyl, alkynyl, cycloalkyl and acyl or R4 and R5 may combine to form a ring, wherein a carbon may be optionally substituted by a heteroatom selected from O, S or Nâ€”R6, and wherein R6 is H, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl or carboxyalkyl; n is 0-5; and, m is 1 or 2; with the proviso that when m is 1, Q is selected from OH, CN, carboxyalkyl, Nâ€”(R7)(R8), where R7 and R8 are selected from H, lower alkyl (1-4C), cycloalkyl, aryl, acyl, amido, or where R7 and R8 combine to form a saturated or unsaturated non-imidizole heterocylic ring; said compound, in the amount administered, causing no clinically significant inhibition of cytochrome PA450 activity in the patient.